Novel design and synthesis of modified structure of Carvedilol

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 3, 2011, Pages 175-179

  Hashemzadeh, Mehrnoosh ^a,d   Movahed, Mohammad R ^a,c   Russu, Wade A ^b   Soroush, Ladan ^d   Hill, Diné N ^d  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^d WHITTIER COLLEGE   (United States)

Author keywords

Acute coronary syndrome; Carvedilol; Coreg; Coreg cr; Heart failure; blocker

Indexed keywords

8 FLUORO 1, 2, 3, 9 TETRAHYDRO 4H CARBAZOL 4 ONE; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARBAZOLE DERIVATIVE; CARVEDILOL; CELIPROLOL; DRUG ANALOG; FLUORINE; LABETALOL; LONG ACTING DRUG; METOPROLOL; NEBIVOLOL; PINDOLOL; PROPRANOLOL; UNCLASSIFIED DRUG; XAMOTEROL;

ARTICLE; CARDIAC PATIENT; CONTROLLED RELEASE FORMULATION; DRUG ACTIVITY; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; HUMAN; PATENT; PRIORITY JOURNAL; SYSTOLIC HEART FAILURE;

EID: 80053539849     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489011797376988     Document Type: Article

References (20)

1. Packer M. B-bolckade in heart failure. Amer J Hypert 1998; 11: 23S.
2. Ronnie W. The current role of beta-blockers in chronic heart failure: With special emphasis on the CIBIS III trial. Eur Heart J Suppl 2009; 11 (Suppl A): A15-A20
3. Abraham, William T. B-blockers. Arch Intern Med 2000; 160:1237.
4. Kai CW, Helmut D. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial Carvedilol as the Sun and Center of the β-Blocker World?. Circulation 2002; 106: 2164.
5. Milton P, Michael RB, Jay NC, Wilson SC, Michael BF, Edward MG, et al. The U.S. carvedilol heart failure study group "the effect of carvedilol on morbidity and mortality in patients with chronic heart failure". N Engl J Med 1996; 334: 1349-55.
6. Turner K. A Review of U.S. Patents in the Field of Organic Process Development Published During February and March 2009. Org Process Res Dev 2009; 4: 556.
7. Kramer JH, Weglicki WB. A hydroxylated analog of the β-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Free Radical Biol Med 1996; 21: 822.
8. Lenarda A, Willem JR, Andrew C, John GFC, Beatrix L, Marco M, et al. Exchange of h-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Eur J Heart Failure 2005; 644.
9. Tenbrink, R.E. Aminoalkoxy carbazoles for the treatment of cns diseases. WO2001017963 (2001).
10. Kankan, R.N., Maharashtra, R.R. Process for the preparation of carvedilol. WO2005113502 (2010)
11. Ruffolo RR, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovascul Pharmacol 1998; 32: S22-S30.
12. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. "Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94(11): 2807-16.
13. Feuerstein MD, Giora ZB, Antoine R, Robert R. Protective effect of carvedilol in the myocardium. Amer J Cardiol 1997; 80(2-1): 41L-45L.
14. Feuerstein GZ, Shusterman, NH, Ruffolo RR. Carvedilol update IV: Prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure. Drugs Today 1997; 33(7): 453-73.
15. Ruffolo RR, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovascul Pharmacol 1998; 32: S22-S30.
16. Möllendorff E, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clini Pharmacol 1987; 33(5): 511-3.
17. Nemergut G. Review of carvedilol in extended-release formulation. Pharmcotherap Perspectives 2007; 46-9.
18. Kazuya I, Shigehiro T, Hiroki M, Yuichiro K, Masato T, Yukiya H. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. Biol Pharm Bull 2009; 31(6): 1297-1300.
19. Liversidge, G., Jenkins, S. Nanoparticulate carvedilol formulations. US20070202180 (2007).
20. Trepat, G., Elisenda, M.A., Anna, P.M., Marta, M.O. Process for the preparation of carvedilol and its enantiomers. US20090005429 (2009).